Fundraising FoxRenovoderm
Columbus, US · Founded 2016 · Delaware LLC · 1 known investors
Find your way into Renovoderm
13 people in our graph share verified history with the Renovoderm team — schools, employers, funds. One of them is your warm intro.
Kourtney Bakerunlockedknows Ronald Bracken · together at The University of Southern Mississippi
×11knows the team · via The University of Southern Mississippi
RenovoDerm is a life sciences company developing wound care and tissue technology platforms within the medtech and biotech sectors. It operates as a commercial subsidiary of Paragen Technologies.
Founders & leadership
RB
Ronald BrackenChief Executive OfficerHe brings over 30 years of research and development experience across medical device sectors including infection control, vascular products, wound care, and implant technologies, with expertise in product development, regulatory processes, and manufacturing.
HD
Hilary DixonChief Commercial Officer
RB
Rodolfo BellesiNamed on SEC filing
FL
Flavio LobatoNamed on SEC filing
RK
Ross KayuhaNamed on SEC filing
ML
Mario LonghiNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$1M disclosed across 3 rounds · 2021–2024
▶$275KraisedMay 2024 · 6 investors · Other Health CareRule 506(b)
▶$275KraisedMay 2024 · 6 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Robert LeeDirector
- David MoritzDirector
- Ronald BrackenExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $275K
- First sale
- Jan 2023
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$250KraisedMay 2024 · 2 investors · Other Health CareRule 506(b)
▶$250KraisedMay 2024 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Ronald BrackenExecutive Officer, Director
- Robert LeeDirector
- David MoritzDirector
- Offering amount
- $500K
- Amount sold
- $250K
- First sale
- May 2024
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$500KraisedJan 2021 · 1 investors · Other Health CareRule 506(b)
▶$500KraisedJan 2021 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Rodolfo BellesiDirector
- Flavio LobatoDirector
- Ronald BrackenExecutive Officer, Director
- Ross KayuhaDirector
- Mario LonghiDirector
- Offering amount
- $1M
- Amount sold
- $500K
- First sale
- Jan 2021
- Incorporated
- Limited Liability Company, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
OrganogenesisOrganogenesis is a regenerative medicine company that develops and commercializes products for the advanced wound care and surgical biologics markets, supplying clinicians and their patients. Its product portfolio includes tissue-based therapies such as Apligraf for wound care.
Globus MedicalGlobus Medical designs and manufactures spine, trauma, and robotic surgical products for the orthopedic medical device market. The company serves hospitals and surgical centers globally.
Smith+NephewSmith+Nephew is a medical technology company that develops products for the repair, regeneration, and replacement of soft and hard tissue, including sports medicine solutions for treating sporting injuries. Its technology is used by surgeons to help patients recover and regain mobility.
Companies working in the same space as Renovoderm.
Frequently asked questions
- What does Renovoderm do?
- RenovoDerm is a life sciences company developing wound care and tissue technology platforms within the medtech and biotech sectors. It operates as a commercial subsidiary of Paragen Technologies.
- Who are Renovoderm's investors?
- Renovoderm's investors include Monte Carlo Capital.
- How much funding has Renovoderm raised?
- Renovoderm has disclosed $1M raised across 3 rounds.
- Where is Renovoderm headquartered?
- Renovoderm is headquartered in Columbus, US.